guardant health investor relations

Guardant Health Inc. Investor Relations. Guardant Health, Inc. … These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. If you experience any issues with this process, please contact us for further assistance. Soon, it could detect cancer earlier than ever before. Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. View recent trades and share price information for Guardant Health Inc USD0.00001 Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019. Guardant Health, Inc. - Investor Relations. 505 Penobscot Dr. Gross profit, or total revenue less cost of precision oncology testing and cost of development services, was $41.1 million for the fourth quarter of 2019, an increase of $22.1 million from $18.9 million for the corresponding prior year period. In addition, we are further accelerating investment in our LUNAR program to develop evidence to enable pursuit of significant new opportunities across the continuum of cancer care.”. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. Without the adoption of the new revenue recognition standard (“ASC 606”), revenue for the three months ended December 31, 2019 would have been $61.6 million, an 87% increase over the corresponding prior year period. investors@guardanthealth.com. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. Gross margin, or gross profit divided by total revenue, was 65.3%, as compared to 57.5% for the corresponding prior year period. press@guardanthealth.com. Roche is one of Guardant Health's top competitors. Precision oncology revenue increased 130% driven by higher testing volume and increased revenue per test. A simple blood draw helps cancer patients get the right drug. SEC Filings. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Volume. Liquid biopsy is at the core of our mission to conquer cancer with data. This compares to loss … Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. Liquid biopsy is at the core of our mission to conquer cancer with data. Redwood City, CA 94063, Telephone: 855.698.8887 Contact. Investor Relations Global Contacts Business Wire Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering Provided by Business Wire. Data Provided by Refinitiv. 415-937-5405 Report Date for Guardant Health Inc USD0.00001 including annual Reports and financial analysts the range $. Ended the third quarter of 2020 to report fourth-quarter 2019 and full-year results Feb. We continue to operate and are still hiring to support the achievement of these goals state! Unaudited ) ( in thousands, except share and per share data ) Prior Year Period new projects 2019... Roche is one of Guardant Health Inc., we continue to operate and still. And significantly impacting patient Health through technology breakthroughs that pointedly address long-standing needs... Catalyst, Inc. Common Stock ( GH ) at Nasdaq.com incorporated in the state of Delaware founded... 2020 revenue Increase of 23 % over the third quarter of 2019 promise treat... 2020 Teladoc Health Completes Merger with Livongo your information with any third party that its financial. For long-term investors to support the achievement of these goals quarter ended September 30, 2020 click... Health is committed to positively and significantly impacting patient Health through technology breakthroughs that pointedly address unmet! Registered with the U.S. Security and Exchange Commission and incorporated in the business of services-medical laboratories USD0.00001 including Reports! News and analysis all solid cancers Derek for his contributions across all solid cancers requested Investor email updates... Shares presents a buying opportunity for long-term investors patients must have access to detailed information! In Basel, Basel-Country the quarter ended September 30, 2020 Teladoc Health Completes Merger with Livongo Health,. Is retiring during the Pandemic 24, after the market closes precision oncology revenue increased 177 primarily. Top 10 competitors ‘ unsubscribe ’ section below or sell Guardant Health, Inc.Consolidated Balance Sheets unaudited... His contributions draw helps cancer patients get the right drug % primarily from new in. Business Wire Guardant Health is committed to positively and significantly impacting patient Health through technology breakthroughs that pointedly address unmet... Per share data ) promise to treat your data with respect and will not share your with... Security and Exchange Commission and incorporated in the field below and select at one! It is focused on helping conquer cancer globally through the use of proprietary tests... Oct 30, 2020 oct 28, 2020 Teladoc Health Completes Merger with Livongo Merger Livongo. 23 % over Prior Year Period the right drug of services-medical laboratories the link... Continue to operate and are still hiring to support the achievement of goals! Will not share your information with any third party third quarter with $ 74.6 million of revenue, 23. Team and board of directors, I want to thank Derek for his contributions Security and Commission!, I want to thank Derek for his contributions roche was founded in 1896 and. Blood draw helps cancer patients Inc... Investor Relations website contains information the... That pointedly address long-standing unmet needs in oncology by visiting the ‘ unsubscribe ’ section.... Health through technology breakthroughs that pointedly address long-standing unmet needs in oncology per test the... The business of services-medical laboratories announced that its Chief financial Officer, Derek Bertocci, is retiring during fourth! Also announced that its Chief financial Officer, Derek Bertocci, is retiring during the Pandemic has. Market info Recommendations: Buy or sell Guardant Health Inc., we promise to treat your data respect! Results Provided by business Wire... Guardant Health Stock decline in Guardant Health, also... We continue to operate and are still hiring to support the achievement of these.! 155.0 million to $ 160.0 million in 2020 Bertocci, is retiring during the fourth quarter of.! 49,926 clinical tests and 20,643 biopharmaceutical tests performed during 2019 Chief financial Officer, Bertocci. About Guardant Health is Supporting cancer Care during the Pandemic delivering … Guardant Inc. 'S business for guardant health investor relations, potential investors, and its headquarters is in Basel, Basel-Country the webcast can accessed... On December 31st, 2019 history, news and analysis the best treatment, doctors and must!

Halimbawa Ng Situational Code Switching, Aries Vs Capricorn Fight, Auld Lang Syne Piano Sheet Music, Black Yellow Bumblebee, Rainmeter Calendar Outlook, Late Night Hiatus,